Dermavant names John Darden as new head of marketing

US immuno-dermatology specialist biotech Dermavant Sciences, a subsidiary of Roivant Sciences, has appointed John Darden as vice president of marketing.

Prior to joining Dermavant, Mr Darden was with US biotech major Amgen (Nasdaq; AMGN) for 15 years, starting as a sales representative for Enbrel (etanercept). He launched several products in marketing including Prolia (denosumab) and Evenity (romosozumab) for post-menopausal osteoporosis and Corlanor  (ivabradine) for heart failure. He also spent significant time in US Value & Access, most recently refining payer coverage strategy to enhance coverage for both Enbrel and Otezla.

Starting in 2020, Mr Darden was the executive director of marketing for Otezla in the USA, where he led the transition of the brand into Amgen after the acquisition of Otezla (apremilast). Mr Darden built out the Amgen brand team, launched the expanded Otezla psoriasis indication in 2022 and advanced both HCP and Consumer marketing efforts in a highly competitive market.